Hansa Medical has appointed Søren Tulstrup as its new chief executive officer and president, roles that will see him succeed acting CEO Ulf Wiinberg who reverts to his former role as chairman of the Swedish biopharma.
Tulstrup was most recently CEO of Swiss pharmaceutical group Vifor Pharma and prior to this he served as senior vice president, global franchise head at Shire.
Ulf Wiinberg, chairman at Hansa Medical, said: “Søren is an accomplished life science industry executive, who brings diverse and extensive industry experience having built and led high-performance biopharma companies, country operations and teams both in Europe and the US.”
Additionally, Tulstrup has served as CEO of Santaris Pharma, now part of Roche, and in several senior commercial roles within Merck & Co and Sandoz Pharma.
Wiinberg concluded: “Søren’s strong track record of managing the development, launch and growth of biopharmaceuticals globally for the treatment of rare diseases and kidney diseases greatly matches Hansa Medical’s promising position.”